The treatment landscape for B-cell malignancies—including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL)—has grown tremendously in the past few years. While front-line treatment still focuses on chemotherapy, targeted options such as Bruton’s tyrosine kinase inhibitors are now being used more frequently in the second-line setting. While these agents offer improved outcomes for patients with B-cell malignancies, they also present challenges with adverse events (AEs), which hematology/oncology clinicians must be able to recognize and manage. This video lecture disseminates data from recent clinical trials and provides expert guidance on identifying, managing, and educating patients on AEs that may occur as a result of these targeted therapies.
Interactive video lecture
After completing this activity, participants should be better able to:
- Identify AEs associated with targeted treatment strategies for CLL/SLL and MCL
- Apply recommended management strategies for AEs of targeted therapy in CLL/SLL and MCL
- Integrate strategies to educate patients on recognition and management of AEs associated with targeted therapies for CLL/SLL and MCL
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 16, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Astellas and Pﬁzer; AstraZeneca; Bristol-Myers Squibb; Dendreon Pharmaceuticals LLC; Eisai; Epizyme Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals, Inc. and Sanoﬁ Genzyme; Seagen Inc. formerly Seattle Genetics.
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Flinn: consulting (paid to institution): AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Iksuda Therapeutics, Janssen, Juno, Kite Pharma, MorphoSys, Novartis, Nurix, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, Yingli; research support (paid to institution): AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharma, Curis, Forma Therapeutics, Forty Seven, Genenetech, Gilead Sciences, IGM BioSciences, Incyte, Infinity Pharma, Janssen, Juno, Karyopharm, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Triphase, Unum Therapeutics, Verastem.
Ms Sandy: speakers bureau: AstraZeneca, Jazz, Merck, Takeda.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 17, 2021
Expiration date: August 16, 2022
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 100621O-7A